This description is a summary of our understanding of the job description. Click on 'Apply' button to find out more.

Role Description

We are seeking a dynamic and self-motivated Thought Leader Liaison to lead field marketing efforts, including Key Opinion Leader identification and management, speaker bureau management, and local/ regional patient advocacy engagements. The ideal candidate will bring a strong field marketing background, excellent communication skills, and a proven ability to build meaningful relationships with both healthcare professionals and patients.

• KOL (Key Opinion Leader) Healthcare Provider Identification and Engagement
• Market Insight Gathering on current disease management landscape
• Speaker Bureau Management, including HCP Speaker Identification, Engagement and Training and HCP Speaker Bureau Content Creation
• HCP and Patient Congress Engagements, including KOL interactions with Invivyd Leadership
• Support and Execution of Strategic Marketing Initiatives
• Proactive interactions with KOLs to validate and optimize brand strategies
• Collaboration on the development of HCP and Patient marketing materials to support effective HCP and Patient Engagement
• Collaboration with local/ regional advocacy groups to develop and coordinate community engagement webinars aimed at improving patient awareness and understanding of the disease and management options

Qualifications

• 7+ years of experience in pharmaceutical or biotechnology sales, or, with a focus on institutional customers
• Field marketing or HCP marketing experience
• In-depth knowledge of the healthcare industry, specifically institutional accounts
• Experience in hematology, transplant, rheumatology, and Infectious disease preferred
• Proven track record of successfully managing Key Opinion Leaders and complex accounts
• Proven record of meeting or exceeding business KPIs
• Analytical mindset with the ability to interpret data, market trends, and customer insights
• Experience working in Veeva and CRM systems and sales analytics tools
• Ability to travel as required up to ~75% of the time to meet with customers and attend industry events

Company Description

At Invivyd, Inc., we take those numbers very seriously and we come to work each day on a mission to deliver protection from serious viral infectious diseases, beginning with SARS-CoV-2. Invivyd deploys a proprietary integrated technology platform unique in the industry designed to assess, monitor, develop, and adapt to create best in class antibodies.

• In March 2024, Invivyd received emergency use authorization (EUA) from the U.S. FDA for a monoclonal antibody (mAb) in its pipeline of innovative antibody candidates.
• In October 2025, the FDA cleared the company's Investigational New Drug (IND) application and provided feedback to advance the company's REVOLUTION clinical program, Invivyd's development program for VYD2311, a vaccine alternative monoclonal antibody being investigated for the prevention of COVID-19.